• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Lipocine Inc.

    12/23/25 3:49:40 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LPCN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Lipocine Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    53630X203

    (CUSIP Number)


    12/18/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    53630X203


    1Names of Reporting Persons

    Squadron Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    444,632.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    444,632.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    444,632.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    53630X203


    1Names of Reporting Persons

    Squadron Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    500,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    500,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    CUSIP No.
    53630X203


    1Names of Reporting Persons

    Matthew Sesterhenn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    500,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    500,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    53630X203


    1Names of Reporting Persons

    William Blank
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    500,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    500,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Lipocine Inc.
    (b)Address of issuer's principal executive offices:

    675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UTAH, 84108.
    Item 2. 
    (a)Name of person filing:

    Squadron Master Fund LP Squadron Capital Management, LLC Matthew Sesterhenn William Blank
    (b)Address or principal business office or, if none, residence:

    Squadron Master Fund LP c/o Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559 Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559 Matthew Sesterhenn c/o Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559 William Blank c/o Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559
    (c)Citizenship:

    Squadron Master Fund LP - Delaware Squadron Capital Management, LLC - Delaware Matthew Sesterhenn - United States William Blank - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    53630X203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Squadron Capital Management, LLC is an investment adviser that is registered as an Exempt Reporting Adviser with the Securities and Exchange Commission. Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the "Funds"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds. Mr. Sesterhenn and Mr. Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein. Squadron Master Fund LP - 444,632 shares Squadron Capital Management, LLC - 500,000 shares Matthew Sesterhenn - 500,000 shares William Blank - 500,000 shares
    (b)Percent of class:

    Ownership percentage is based on 5,551,931 shares of common stock outstanding, par value $0.0001 per share, as of November 5, 2025, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. Squadron Master Fund LP - 8.0% Squadron Capital Management, LLC - 9.0% Matthew Sesterhenn - 9.0% William Blank - 9.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Squadron Master Fund LP - 0 Squadron Capital Management, LLC - 0 Matthew Sesterhenn - 0 William Blank - 0

     (ii) Shared power to vote or to direct the vote:

    Squadron Master Fund LP - 444,632 shares Squadron Capital Management, LLC - 500,000 shares Matthew Sesterhenn - 500,000 shares William Blank - 500,000 shares

     (iii) Sole power to dispose or to direct the disposition of:

    Squadron Master Fund LP - 0 Squadron Capital Management, LLC - 0 Matthew Sesterhenn - 0 William Blank - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Squadron Master Fund LP - 444,632 shares Squadron Capital Management, LLC - 500,000 shares Matthew Sesterhenn - 500,000 shares William Blank - 500,000 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Notes above.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Squadron Master Fund LP
     
    Signature:/s/ Matthew Sesterhenn
    Name/Title:Partner, Squadron Partners LLC, its General Partner
    Date:12/23/2025
     
    Squadron Capital Management LLC
     
    Signature:/s/ Matthew Sesterhenn
    Name/Title:Partner
    Date:12/23/2025
     
    Matthew Sesterhenn
     
    Signature:/s/ Matthew Sesterhenn
    Name/Title:Matthew Sesterhenn
    Date:12/23/2025
     
    William Blank
     
    Signature:/s/ William Blank
    Name/Title:William Blank
    Date:12/23/2025
    Get the next $LPCN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LPCN

    DatePrice TargetRatingAnalyst
    8/26/2021$2.50 → $3.50Buy
    HC Wainwright & Co.
    6/24/2021$3.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $LPCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    2026 Asset Growth: Why Federal Compliance Is the New Metric

    VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using aggressive buyouts as a primary 2026 strategy to secure high-tech efficiency while navigating intense federal scrutiny and capital limits[2]. In this high-stakes environment, companies with a clear and proven path through federal guidelines are capturing the most attention, including Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Canopy Growth (NASDAQ:CGC) (TSX:WEED), Definium Therap

    1/19/26 12:20:49 PM ET
    $CGC
    $DFTX
    $KDP
    Medicinal Chemicals and Botanical Products
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

    Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomizedNo drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reportedStudy is no longer screening new participantsSALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN

    1/12/26 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

    Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second quarter of 2026SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced 80% completion of enrollment in the ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD, with 66 of the 80 planned study participants randomized. In addition, the second of two independent Data Safety Monitoring Board reviews is planned for early-January 2026. Following the

    12/16/25 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TESTOSTERONE UNDECANOATE issued to LIPOCINE INC

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    3/29/22 4:34:43 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for TESTOSTERONE UNDECANOATE

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Tentative Approval' on 12/08/2020. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    12/20/20 4:30:41 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Lipocine with a new price target

    HC Wainwright & Co. reiterated coverage of Lipocine with a rating of Buy and set a new price target of $3.50 from $2.50 previously

    8/26/21 6:33:21 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Lipocine with a new price target

    Cantor Fitzgerald initiated coverage of Lipocine with a rating of Overweight and set a new price target of $3.00

    6/24/21 7:18:29 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Lipocine with a new price target

    HC Wainwright & Co. reiterated coverage of Lipocine with a rating of Buy and set a new price target of $2.50 from $3.00 previously

    5/27/21 6:10:57 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Patel Mahesh V.

    4 - Lipocine Inc. (0001535955) (Issuer)

    1/5/26 3:50:00 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Patel Mahesh V.

    4 - Lipocine Inc. (0001535955) (Issuer)

    12/19/25 5:09:42 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Fogarty Krista

    4 - Lipocine Inc. (0001535955) (Issuer)

    12/19/25 5:07:29 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    SEC Filings

    View All

    SEC Form 8-K filed by Lipocine Inc.

    8-K - Lipocine Inc. (0001535955) (Filer)

    1/12/26 4:25:07 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Lipocine Inc.

    8-K - Lipocine Inc. (0001535955) (Filer)

    1/12/26 9:30:22 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Lipocine Inc.

    SCHEDULE 13G - Lipocine Inc. (0001535955) (Subject)

    12/23/25 3:49:40 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    Leadership Updates

    Live Leadership Updates

    View All

    LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS

    Industry veterans Jill M. Jene, Ph.D. and Spyros Papapetropoulos M.D. Ph.D. appointed to Board SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors. "We are very pleased to welcome Jill Jene and Spyros Papapetropoulos to our board of directors. Each of them brings a wealth of relevant expertise," said Mahesh V. Patel, Ph.D., Chairman and CEO of Lipocine.  "J

    4/11/22 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Lipocine Inc. (Amendment)

    SC 13G/A - Lipocine Inc. (0001535955) (Subject)

    2/10/22 8:22:26 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Lipocine Inc. (0001535955) (Subject)

    2/10/21 2:41:32 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - Lipocine Inc. (0001535955) (Subject)

    2/10/21 11:14:29 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPCN
    Financials

    Live finance-specific insights

    View All

    Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

    SALT LAKE CITY, Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter ended September 30, 2025 and provided a corporate update. Neuroactive Steroids (NAS) LPCN 1154 for Postpartum Depression (PPD) LPCN 1154 (oral brexanolone) is a non-invasive, rapid onset, oral formulation of the neuroactive steroid brexanolone that Lipocine is developing for the treatment of PPD.A Phase 3 safety and ef

    11/6/25 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

    SALT LAKE CITY, Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update. Neuroactive Steroids LPCN 1154 (oral brexanolone product candidate) is a non-invasive, 48-hour treatment option targeted for rapid symptom relief of postpartum depression (PPD), a serious unmet medical need. LPCN 1154 could have advantages with respect to limitat

    8/5/25 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

    SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2025 and provided a corporate update. Neuroactive Steroids Lipocine has initiated an outpatient Phase 3 safety and efficacy study of LPCN 1154, a non-invasive, rapid onset, oral formulation of brexanolone for the treatment of postpartum depression (PPD). Dosing of the first patient is anticipated in the s

    5/8/25 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care